At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating SAN007 5% cream, Placebo, and 1 other intervention for Atopic Dermatitis and Eczema. Completed, enrolled 71 participants across 5 sites.
Detailed Summary
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients at least 18 years of age, with atopic dermatitis.
Study Details
Timeline
Interventions
5% EISO in a cream formulation applied twice a day for up to 28 days.
A placebo cream containing the same components as the vehicle for the active intervention arm
10% EISO in a cream formulation applied twice a day for up to 28 days.